Therapeutic strategies for the management of hypertension have improved substantially since their inception more than 50 years ago. In recent years, new agents that block the action of the reninangiotensin system have been developed, adding significantly to the antihypertensive arsenal now available to physicians.
A major advance took place during the 1990s with the introduction of the first generation of nonpeptide angiotensin II (A II) receptor antagonists. These agents are more specific than angiotensinconverting enzyme (ACE) inhibitors in terms of A II blockade, and are well tolerated, with a placebo-like side-effect profile.
There is now sufficient evidence of the safety and efficacy of A II receptor antagonists to justify their use as first-line therapy in hypertension. The newest of these agents, olmesartan medoxomil, is an orally active drug with a favourable pharmacological profile. The medoxomil ester is a prodrug that is rapidly converted to the active metabolite, olmesartan, in vivo. Olmesartan from olmesartan medoxomil tablets demonstrates good bioavailability and has a long half-life: two advantages that make olmesartan medoxomil ideal for once-daily dosing.
As the following series of articles makes clear, A II receptor antagonists in general -and olmesartan in particular -compare favourably to other well-estabCorrespondence: T Fujita, Department of Internal Medicine, University of Tokyo, 3-28-6 Mejirodai, Bunkyo-ku, 112-8688 Tokyo, Japan. E-mail: fujita-disȰh.u-tokyo.ac.jp lished antihypertensive agents. Furthermore, it has been shown that these agents have the potential to reduce cardiovascular mortality and morbidity to a greater degree than can be explained by reduction of blood pressure alone. Many of the processes that lead to atherosclerotic disease may be prevented by A II receptor antagonists -irrespective of their effect on plasma lipids and blood pressure.
The clinical and pharmacological profiles of olmesartan have now been examined in detail. Evidence is emerging that this is a new A II receptor antagonist that may allow physicians to lower blood pressure safely and effectively. In addition, together with its possible anti-atherosclerotic effect (regardless of blood pressure lowering), olmesartan may have an important role in reducing the burden of many cardiovascular, cerebrovascular and renal vascular diseases.
Despite clear benefits achieved with antihypertensive drugs, diagnosis, treatment and control of hypertension continue to disappoint. This is a major challenge confronting clinicians in both primary and secondary care. Closer attention to the recommendations of international guidelines for the management of hypertension and more widespread use of safe and effective antihypertensive medication will help to resolve this dilemma.
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